Related Experiment Video
Updated: Apr 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma
Pauline du Rusquec1, Melanie Saint-Jean, Anabelle Brocard
1Departments of *Dermato-Oncology †CIC Biotherapy INSERM U892, Hôtel-Dieu University Hospital, Nantes, France.
Abstract:
A 77-year-old patient treated with ipilimumab (anti-CTLA-4 antibody) for metastatic melanoma developed autoimmune pancytopenia (anemia, thrombocytopenia, and neutropenia) 8 days after the fourth infusion. This pancytopenia was resistant to high-dose oral corticosteroids (1 mg/kg) and to hematopoietic growth factors. It resolved after intravenous immunoglobulins injection. To date, only 1 case of autoimmune pancytopenia has been reported after this treatment. According to the case that we report, it seems essential to control the leukocyte count before any injection of ipilimumab.
Related Concept Videos
Tumor Immunotherapy
The Intrinsic Apoptotic Pathway

